Sugi Predict

Sugi Predict / Targets / CACNA1I

CACNA1I

Voltage-dependent T-type calcium channel subunit alpha-1I · Q9P0X4 · CACNA1I on Sugi Atlas →

28,760 patent compounds predicted against CACNA1I, 13,242 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL842704 SCHEMBL842704 0.38 14/20
SCHEMBL116362 SCHEMBL116362 0.45 11/20
SCHEMBL78090 SCHEMBL78090 0.58 8/20
SCHEMBL1047744 SCHEMBL1047744 0.55 8/20
SCHEMBL943655 SCHEMBL943655 0.46 7/20
SCHEMBL619154 SCHEMBL619154 0.41 7/20
SCHEMBL620978 SCHEMBL620978 0.40 7/20
SCHEMBL621013 SCHEMBL621013 0.40 7/20
Suvecaltamide Suvecaltamide (SCHEMBL1065999) 1.00 6/20
SCHEMBL1064366 SCHEMBL1064366 0.83 6/20
SCHEMBL1063192 SCHEMBL1063192 0.78 6/20
SCHEMBL1064587 SCHEMBL1064587 0.78 6/20
SCHEMBL1062930 SCHEMBL1062930 0.70 6/20
SCHEMBL1062015 SCHEMBL1062015 0.69 6/20
SCHEMBL1060481 SCHEMBL1060481 0.60 6/20
SCHEMBL1060494 SCHEMBL1060494 0.56 6/20
SCHEMBL429257 SCHEMBL429257 0.50 6/20
SCHEMBL621555 SCHEMBL621555 0.39 6/20
SCHEMBL617973 SCHEMBL617973 0.38 6/20
SCHEMBL1058794 SCHEMBL1058794 0.83 5/20

Clinical trials — most relevant to CACNA1I by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination PHASE4UNKNOWN
Role of Intralipid in Management of Organophosphorus Poisoning PHASE2/PHASE3WITHDRAWN
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy PHASE3COMPLETED
Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine. PHASE3COMPLETED
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome PHASE1/PHASE2NOT_YET_RECRUITING
4-Aminopyridine in Episodic Ataxia Type 2 PHASE2WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients PHASE2WITHDRAWN
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients PHASE2WITHDRAWN
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain PHASE2COMPLETED
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators. PHASE2NOT_YET_RECRUITING
Physiologic Effects of Topiramate on Cognition PHASE1COMPLETED
Verapamil in Supraclavicular Brachial Plexus Block nanUNKNOWN
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY) nanCOMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development nanRECRUITING
Evaluation of A Clinical Diagnostic Test for CRDS nanRECRUITING
Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism nanCOMPLETED
International CRDS Registry nanRECRUITING
Role of Calcium Channels in Vascular Function nanCOMPLETED
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study nanUNKNOWN
The Prevalence of RYR1-related Disease nanNOT_YET_RECRUITING
The Use of Antiarrhythmic Drugs in Pediatrics nanUNKNOWN
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13) nanNOT_YET_RECRUITING
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED
Post-stroke Epilepsy: Primary Prophylaxis Study nanUNKNOWN
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors nanUNKNOWN
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Direct Cortical Measurement of the Intensity and Pattern of Current Flow Produced by TDCS nanCOMPLETED
Postoperative Pain Alleviation in Open Heart Surgery nanCOMPLETED
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CACNA1I binder may also engage these)

ProteinNameSimilarity
CACNA1H Voltage-dependent T-type calcium channel subunit alpha-1H 1.000 landscape →
CACNA1G Voltage-dependent T-type calcium channel subunit alpha-1G 1.000 landscape →
Q9Z0Y8 — 0.999 Q9Z0Y8 →
O54898 — 0.998 O54898 →
Q05152 — 0.997 Q05152 →
Q9EQ60 — 0.997 Q9EQ60 →
P15389 — 0.996 P15389 →
O88427 — 0.995 O88427 →
Q9JJV9 — 0.994 Q9JJV9 →
P54282 — 0.994 P54282 →
SCN5A Sodium channel protein type 5 subunit alpha 0.994 landscape →
Q62968 — 0.993 Q62968 →
CACNA1B Voltage-dependent N-type calcium channel subunit alpha-1B 0.993 landscape →
P97445 — 0.992 P97445 →
Q02343 — 0.992 Q02343 →
Q6QIY3 — 0.992 Q6QIY3 →
Q07652 — 0.991 Q07652 →
Q9TUI4 — 0.991 Q9TUI4 →
Q61290 — 0.991 Q61290 →
CACNA1A Voltage-dependent P/Q-type calcium channel subunit alpha-1A 0.991 landscape →
Q02294 — 0.990 Q02294 →
P27732 — 0.990 P27732 →
SCN10A Sodium channel protein type 10 subunit alpha 0.990 landscape →
P15390 — 0.990 P15390 →
Q61762 — 0.989 Q61762 →
O55017 — 0.989 O55017 →
P56698 — 0.989 P56698 →
CACNA1E Voltage-dependent R-type calcium channel subunit alpha-1E 0.989 landscape →
P19024 — 0.988 P19024 →
Q28371 — 0.988 Q28371 →